Colazal is owned by Valeant Pharms Intl.
Colazal contains Balsalazide Disodium.
Colazal has a total of 4 drug patents out of which 0 drug patents have expired.
Colazal was authorised for market use on 18 July, 2000.
Colazal is available in capsule;oral dosage forms.
Colazal can be used as treatment of ulcerative colitis.
The generics of Colazal are possible to be released after 24 February, 2027.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7625884 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(3 years from now) | |
US7452872 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(3 years from now) | |
US7625884
(Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(4 years from now) | |
US7452872
(Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(4 years from now) |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 18 July, 2000
Treatment: Treatment of ulcerative colitis
Dosage: CAPSULE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic